Thirteen laboratories collaborated to optimize interlaboratory agreement of results of a broth macrodilution procedure for testing three classes of antifungal drugs against pathogenic yeasts. The activities of amphotericin B, flucytosine, and ketoconazole were tested against 100 coded isolates of Candida albicans, Candida tropicalis, Candida parapsilosis, Candida lusitaniae, Torulopsis (Candida) glabrata, and Cryptococcus neoformans. Two starting yeast inoculum sizes (5 x 104 and 2.5 x 103 cells per ml) were compared, and readings were taken after 24 and 48 h of incubation. All other test conditions were standardized. The resultant turbidities in all tubes were estimated visually on a scale from 0 to 4+ turbidity, and MIC-0, MIC-1, and MIC-2 were defined as the lowest drug concentrations that reduced growth to 0, 1+, or 2+ turbidity, respectively. For flucytosine, agreement among laboratories varied between 57 and 87% for different inocula, times of incubation, and end point criteria. Agreement was maximized (85%) when the lower inoculum was incubated for 2 days and the MICs were defined as 1+ turbidity or less. For amphotericin B, variations in test conditions produced much smaller differences in interlaboratory agreement. For ketoconazole, interlaboratory agreement was poorer by all end point criteria. However, MIC-2 endpoints distinguished T. glabrata as resistant compared with the other species. Overall, the studies indicated that readings from the lower inoculum obtained on the second day of reading result in the greatest interlaboratory agreement. In combination with data from previous multicenter studies (National Committee for Clinical Laboratory Standards, Antifungal Susceptibility Testing: Committee
Fungal infections have emerged as major causes of morbidity and mortality in compromised patient populations. During the last 15 years, the incidence of fungal infections has continued to increase in part because of improved diagnosis and the increasing number of patients with AIDS, organ transplants, malignancies, and other immunocompromising factors (4, 40) . The frequency of fungal infections has greatly increased interest in testing new fungal isolates from patients by clinical laboratories, and efforts to develop standardized methodologies for such tests have been re-ported (18, 27, 33, 39) . In addition, an increasing number of reports suggest that clinically significant resistance exists in some strains (13-15, 19, 22, 37, 38, 43) . Standardized methods of testing isolates would permit the development of a more reliable data base from which to study this clinically relevant issue.
Since standardization is vital to meaningful communication between clinical laboratories and physicians and to the application of in vitro data to patient responses to therapy, the National Committee for Clinical Laboratory Standards formed a subcommittee on antifungal susceptibility testing in 1982. Four years later, the first subcommittee report was published in which the results of a questionnaire and small collaborative study were presented (5, 24) . Among the findings were that most centers used a broth dilution meth-ANTIMICROB. AGENTS CHEMOTHER. odology, only a few isolates were tested annually, Candida albicans or other species of yeasts were the most commonly tested species of fungi, and MIC data among the laboratories that participated in the collaborative study were unacceptably low. Two subsequent multicenter studies (30, 32) have focused on inoculum preparation, inoculum size, selection of synthetic media, temperature and duration of incubation, and end point definition. These studies established criteria for inoculum preparation by using a spectrophotometric method (30) , selection of RPMI 1640 medium (32) , and an incubation temperature of 35°C (32) for antifungal susceptibility testing of yeasts.
The present collaborative study was performed to evaluate the utility of RPMI 1640 medium buffered with morpholinepropanesulfonic acid (MOPS) and an incubation temperature of 35°C in a broth macrodilution susceptibility test method with a panel of 100 pathogenic yeast isolates and three classes of antifungal agents. The effects of inoculum size and incubation times of 24 and 48 h on the ability to determine the susceptibilities of isolates of Candida species, Torulopsis (Candida) glabrata, and Cryptococcus neoformans also were assessed. The data obtained in the present study, when combined with the information gained in the previous studies of the National Committee for Clinical Laboratory Standards (5, 24, 30, 32) , have supported the development of a proposed standardized method for in vitro antifungal susceptibility testing for yeasts.
MATERIALS AND METHODS
Antifungal agents. The following three antifungal agents were used: amphotericin B (Bristol Myers-Squibb), flucytosine (5-FC; Hoffmann-La Roche Laboratories), and ketoconazole (Janssen Pharmaceutica). These agents were obtained from the manufacturers as standard powders, each from a single lot, and were distributed to the participating laboratories. Stock solutions of 16,000 ,ug/ml were prepared in 100% dimethyl sulfoxide (amphotericin B and ketoconazole) or sterile distilled water (5-FC) immediately prior to use in the study. Final dimethyl sulfoxide concentrations in the test drug preparations used were well below the levels shown to have antifungal effects.
Test organisms. A panel of 100 pathogenic yeasts was used in the study. Eighty-five strains of noncryptococcal yeasts were sequentially isolated from cultures of blood from patients treated at the University of Iowa. This panel consisted of 35 strains of C. albicans, 15 strains of Candida tropicalis, 15 strains of Candida parapsilosis, 10 strains of Candida lusitaniae, and 10 strains of T. glabrata. Biochemical and molecular analyses demonstrated that each of the strains possessed one or another unique characteristic (31, 34 Yeast inocula (0.9 ml) were added to polystyrene plastic tubes (12 by 75 mm; Falcon 2054; Becton Dickinson, Lincoln Park, N.J.) containing dilutions of one of the antifungal agents (0.1 ml at a 1Ox final concentration) by using sterile, individual 1-ml pipettes. Each yeast isolate was tested at two inocula, and drug-free and yeast-free control tubes were included. The contents of the tubes were mixed, and racks of loosely capped tubes were incubated without agitation in air at 35°C.
Tubes were examined on the first and second days on which significant growth was evident in the drug-free control tube. For species other than C. neofonnans, this was after 24 and 48 h of incubation. For nearly all isolates of C. neoformans, this was after 48 and 72 h of incubation. At the times of examination, each tube was flicked gently and the turbidity was estimated by using the following scale: 0, optically clear; 1+, slightly hazy; 2+, prominent reduction in turbidity compared with that of the drug-free control; 3+, slight reduction in turbidity compared with that of the drug-free control; 4+, no reduction in turbidity compared with that of the drug-free control. Investigators recorded the estimated turbidity for all tubes on standardized data sheets.
Study design and analysis of results. Each of the 13 participating laboratories received a protocol, antifungal drugs, media, coded yeast isolates, and standardized data sheets. When tests were completed, the data sheets were forwarded to one center where the results were entered into a microcomputer data base (Rbase; Microrim Inc., Redmond, Wash.), and the data were subsequently transferred to a statistical program (Systat; Systat Inc., Evanston, Ill.) for analysis. Listings of the entered data were returned to the reporting laboratory, where the accuracies of the entries were checked and errors were corrected.
The visual estimates of turbidity were used to calculate different end point results. MIC-0, MIC-1, and MIC-2 were Tables 1 and 2 for amphotericin B and 5-FC, respectively. Results for all three end points with ketoconazole are given in Table 3 .
Amphotericin B generally showed the best overall agreement with either MIC-0 or MIC-1 end points. Results ranged from 63 to 97% agreement among the different test conditions and species. Overall, low starting inoculum sizes read on the second day produced optimal agreement, and this was superior to the condition with the next closest percent agreement (Table 4) . With these test conditions, there was no difference in the percent agreement between MIC-0 and MIC-1.
5-FC displayed a wide range of agreement with different test conditions, ranging from 55 to 90% for different species. As with amphotericin B, MIC-0 readings of the lower starting inoculum size on the second day showed significantly better agreement than the next best test condition. However, for MIC-1 readings, second day low-inoculum and first day high-inoculum readings were not significantly different, and both afforded greater agreement than did any MIC-0 end point ( For ketoconazole, all three endpoints are shown in Fig. 3  and 4 , and the modal distributions demonstrated sharply different patterns. MIC-0 results were uniformly higher, most notably for C. albicans, C. tropicalis, and T. glabrata. With MIC-1 and MIC-2 results, end points shifted dramatically lower for C. albicans and C. tropicalis, whereas T. glabrata showed much less of a shift. As a result, by using the MIC-2 end point, for 70% of the T. glabrata isolates the MIC-2 was .2.0 ,ug/ml, whereas for all strains of other species, the MIC-2 was 1.0 p,g/ml.
DISCUSSION
In the present study, results produced with the lower inoculum and interpreted on the second day of readings proved to be significantly more reproducible among laboratories than were found with either the higher inoculum or first day readings. Under optimal conditions, 90% of amphotericin B results for each strain from different laboratories agreed within a fourfold range regardless of the end point Significance of differences between day 1 high-inoculum and day 2 low-inoculum results are provided, but a Bonferroni correction was not applied.
d Low and high indicate inoculum sizes.
e NS, not significant. criterion used. However, with 5-FC and ketoconazole, agreement was improved with MIC-1 and MIC-2, respectively.
The reason that the less stringent end points improved agreement for these two drugs is likely related to the trailing nature of the drug effect documented in past studies; this also would be expected to be evident with other azole congeners such as miconazole and fluconazole (11, 16, 26, 28, 36) . The titration curve for the effect of amphotericin B is much sharper than exists with the other drugs studied. In addition, the onset of the effect of 5-FC and azoles is delayed, allowing growth to proceed for some period before inhibition is initiated (17, 23) . In antibacterial susceptibility testing, an analogous problem has been encountered for sulfa drugs tested by an agar diffusion test; in that circumstance an end point criterion of 80% inhibition has been adopted (2, 3).
Although not specifically examined in the present study, recent parallel studies reported elsewhere (10) have determined that the estimates of turbidity described here as 1+ and 2+ can be approximated by 1:10 and 1:5 dilutions of the drug-free control, respectively. This approach provides a convenient and direct method of establishing a turbidity end point for a specific isolate that precisely reflects 90 and 80% inhibition, respectively, and further reduces the likelihood of interobserver error. (20, 21, 41, 42) . In contrast, the MIC-0 criterion did not distinguish T. glabrata from other species. Not tested in this study but of additional interest would be the MICs for isolates of Candida krusei, which has also been associated with azole resistance (1, 6, 8, 12, 29, 35, 44) . In a future study, it will be important to determine whether the resistance of this species can be identified by the MIC-2 criterion as well.
The amphotericin B susceptibility of C. lusitaniae noted in our results also is of special interest, since a few isolates of this species from some institutions have been reported to be resistant to amphotericin B (7). All of the strains of this species tested in the present study appeared to have susceptibilities identical to those of the other species tested, and this raises the possibility that in attaining optimal interlaboratory agreement, the procedure has become insensitive to potentially important amphotericin B resistance. This important issue needs to be addressed in future studies. This and previous collaborative studies (24, 30, 32) 
